LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 283

Search options

  1. Article ; Online: Report of two siblings with APECED in Serbia: is there a founder effect of c.769C>T AIRE genotype?

    Fierabracci, Alessandra / Lanzillotta, Mariafrancesca / Vorgučin, Ivana / Palma, Alessia / Katanić, Dragan / Betterle, Corrado

    Italian journal of pediatrics

    2021  Volume 47, Issue 1, Page(s) 126

    Abstract: ... differently in different cohorts. Screenings of the population revealed that homozygous AIRE mutations c.769C ... T, c.415C > T and c.254A > G have a founder effect in Finnish, Sardinian and Iranian Jew populations ... revealed a homozygous c.769C > T (R257X (p.Arg257X)) AIRE mutation. We additionally reviewed the literature ...

    Abstract Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) or autoimmune polyglandular syndrome Type 1 is a rare autosomal recessive syndrome. The disorder is caused by mutations in the AIRE (AutoImmune Regulator) gene. According to the classic criteria, clinical diagnosis requires the presence of at least two of three main components: chronic mucocutaneous candidiasis, hypoparathyroidism and primary adrenal insufficiency. Furthermore, patients are often affected by other endocrine or non-endocrine associated autoimmune conditions. The enrichment of the non-classical triad seems to occur differently in different cohorts. Screenings of the population revealed that homozygous AIRE mutations c.769C > T, c.415C > T and c.254A > G have a founder effect in Finnish, Sardinian and Iranian Jew populations respectively.
    Case presentation: We report here the clinical and genetic characteristics of two new Serbian APECED siblings, one male and one female, actual age of 27 and 24 respectively, born from non-consanguineous parents. Addison's disease was diagnosed in the male at the age of 3.5 and hypoparathyroidism at the age of 4. The female developed hypoparathyroidism at 4 years of age. She presented diffuse alopecia, madarosis, onychomycosis, teeth enamel dysplasia. She further developed Addison's disease at the age of 11 and Hashimoto's thyroiditis at the age of 13.5. She had menarche at the age of 14 but developed autoimmune oophoritis and premature ovarian failure at the age of 16. A treatment with hydrocortisone, fludrocortisone and alfacalcidiol was established for both siblings; L-T4 (levo-thyroxine) for thyroid dysfunction and levonorgestrel and etinilestradiol for POF were also administered to the female. Genetic screening revealed a homozygous c.769C > T (R257X (p.Arg257X)) AIRE mutation. We additionally reviewed the literature on 11 previously published Serbian patients and evaluated the frequency of their main diseases in comparison to Finnish, Sardinian, Turkish, Indian and North/South American cohorts.
    Conclusion: A founder effect was discovered for the R257X genotype detected in the DNA of 10 homozygous and 2 heterozygous patients. Of note, all Serbian APECED patients were affected by adrenal insufficiency and 10 out of 13 patients presented CMC.
    MeSH term(s) Adult ; Female ; Founder Effect ; Genotype ; Humans ; Male ; Mutation ; Polyendocrinopathies, Autoimmune/genetics ; Serbia ; Siblings ; Transcription Factors/genetics ; Young Adult ; AIRE Protein
    Chemical Substances Transcription Factors
    Language English
    Publishing date 2021-06-02
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2088556-8
    ISSN 1824-7288 ; 1720-8424
    ISSN (online) 1824-7288
    ISSN 1720-8424
    DOI 10.1186/s13052-021-01075-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Spatial and temporal variability in attenuation of polar organic micropollutants in an urban lowland stream

    Jaeger, Anna / Posselt, Malte / Betterle, Andrea / Schaper, Jonas / Coll Mora, Claudia

    Environmental science & technology, 53(5):2383-2395

    2019  

    Abstract: Contamination of rivers by trace organic compounds (TrOCs) poses a risk for aquatic ecosystems and drinking water quality. Spatially- and temporally-varying environmental conditions are expected to play a major role in controlling in-stream attenuation ... ...

    Institution Leibniz-Institut für Gewässerökologie und Binnenfischerei
    Abstract Contamination of rivers by trace organic compounds (TrOCs) poses a risk for aquatic ecosystems and drinking water quality. Spatially- and temporally-varying environmental conditions are expected to play a major role in controlling in-stream attenuation of TrOCs. This variability is rarely captured by in situ studies of TrOC attenuation. Instead, snap-shots or time-weighted average conditions and corresponding attenuation rates are reported. The present work sought to investigate this variability and factors controlling it by analysis of 24 TrOCs over a 4.7 km reach of the River Erpe (Berlin, Germany). The factors investigated included sunlight and water temperature as well as the presence of macrophytes. Attenuation rate constants in 48 consecutive hourly water parcels were tracked along two contiguous river sections of different characteristics. Section 1 was less shaded and more densely covered with submerged macrophytes compared to section 2. The sampling campaign was repeated after macrophyte removal from section 1. The findings show, that section 1 generally provided more favorable conditions for both photo- and biodegradation. Macrophyte removal enhanced photolysis of some compounds (e.g. hydrochlorothiazide and diclofenac) while reducing the biodegradation of metoprolol. The transformation products metoprolol acid and valsartan acid were formed along the reach under all conditions.
    Language English
    Document type Article
    Database Repository for Life Sciences

    More links

    Kategorien

  3. Article: Is hepatitis C virus a risk factor for thyroid autoimmunity?

    Floreani, A / Betterle, C / Carderi, I / Presotto, F / Pedini, B / Moscon, A / Andrea, O / Chiaramonte, M

    Journal of viral hepatitis

    2006  Volume 13, Issue 4, Page(s) 272–277

    Abstract: The role of hepatitis C virus (HCV) in inducing thyroid autoimmunity is still under discussion and ...

    Abstract The role of hepatitis C virus (HCV) in inducing thyroid autoimmunity is still under discussion and to assess the prevalence of thyroid autoantibodies and thyroid disease in the general population and to analyse the role of HCV in inducing thyroid autoimmunity. We studied 697 subjects residing in Arsita (a small town in central Italy). Thyroid autoantibodies and nonorgan-specific autoantibodies (NOSAs) were tested in each subject, who were also screened for anti-HCV antibodies; all subjects found positive to HCV-RNA were considered as being HCV-infected. Thyroid function tests were performed in all subjects positive for thyroid autoantibody. Seventy-one subjects were found HCV-positive; four of these (5.6%) were positive for at least one thyroid autoantibody, as opposed to 7 (4.9%) of the 142 sex- and age-matched controls of the same population (P = n.s.). Thyroid dysfunction was found in 2/4 HCV-positive, and in 1/7 HCV-negative subjects with thyroid autoantibodies (P = n.s.). NOSAs were significantly more common in HCV-positive than in HCV-negative subjects (P < 0.0001). Hence HCV per se is not responsible for thyroid autoimmune dysfunction, whereas HCV does seem to induce NOSAs. It should be taken into account, however, that the phenotypic expression of autoimmune diseases is obviously influenced by a number of risk factors, including genetic predisposition, female sex and infectious agents, that could trigger the onset of the disease.
    MeSH term(s) Adult ; Age Factors ; Autoantibodies/blood ; Female ; Hepacivirus/immunology ; Hepatitis C Antibodies/blood ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/immunology ; Hepatitis C, Chronic/virology ; Humans ; Italy/epidemiology ; Male ; Middle Aged ; Risk Factors ; Seroepidemiologic Studies ; Sex Factors ; Statistics, Nonparametric ; Thyroid Diseases/epidemiology ; Thyroid Diseases/immunology ; Thyroid Diseases/virology
    Chemical Substances Autoantibodies ; Hepatitis C Antibodies ; thyroid microsomal antibodies
    Language English
    Publishing date 2006-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212497-7
    ISSN 1365-2893 ; 1352-0504
    ISSN (online) 1365-2893
    ISSN 1352-0504
    DOI 10.1111/j.1365-2893.2005.00699.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy.

    Betterle, C / Furmaniak, J / Sabbadin, C / Scaroni, C / Presotto, F

    Journal of endocrinological investigation

    2023  Volume 46, Issue 4, Page(s) 643–665

    Abstract: Background: The number of recognised distinct autoimmune diseases (AIDs) has progressively increased over the years with more than 100 being reported today. The natural history of AIDs is characterized by progression from latent and subclinical to ... ...

    Abstract Background: The number of recognised distinct autoimmune diseases (AIDs) has progressively increased over the years with more than 100 being reported today. The natural history of AIDs is characterized by progression from latent and subclinical to clinical stages and is associated with the presence of the specific circulating autoantibodies. Once presented, AIDs are generally chronic conditions. AIDs have the tendency to cluster and co-occur in a single patient. Autoimmune thyroid diseases (AITD) are the most prevalent of AIDs in the world population, and about one-third of the AITD patients also present with a non-thyroid AID during their life-span. Furthermore, patient with non-thyroid AIDs often presents with a form of AITD as a concurrent condition. Many of the clusters of AIDs are well characterized as distinctive syndromes, while some are infrequent and only described in case reports.
    Purpose: In this review, we describe the wide spectrum of the combinations and the intricate relationships between AITD and the other AIDs, excluding Addison's disease. These combinations are collectively termed type 3 Autoimmune Polyglandular Syndrome (APS-3), also called type 3 Multiple Autoimmune Syndrome (MAS-3), and represent the most frequent APS in the world populations.
    Conclusions: Numerous associations of AITD with various AIDs could be viewed as if the other AIDs were gravitating like satellites around AITD located in the center of a progressively expanding galaxy of autoimmunity.
    MeSH term(s) Humans ; Polyendocrinopathies, Autoimmune/diagnosis ; Polyendocrinopathies, Autoimmune/epidemiology ; Addison Disease ; Autoantibodies ; Hashimoto Disease ; Syndrome
    Chemical Substances 3-aminopropyltrimethoxysilane (13822-56-5) ; Autoantibodies
    Language English
    Publishing date 2023-01-07
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 432272-1
    ISSN 1720-8386 ; 0391-4097 ; 1121-1369
    ISSN (online) 1720-8386
    ISSN 0391-4097 ; 1121-1369
    DOI 10.1007/s40618-022-01994-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Graves' disease after COVID mRNA vaccination for the first time diagnosed in adolescence-case report. Cause and effect relationship or simple coincidence?

    Mainieri, Francesca / Chiarelli, Francesco / Betterle, Corrado / Bernasconi, Sergio

    Journal of pediatric endocrinology & metabolism : JPEM

    2023  Volume 36, Issue 10, Page(s) 993–997

    Abstract: Objectives: Over the past 3 years, coronavirus disease 2019 with its worldwide spread has profoundly marked public health, therefore anti-COVID-19 vaccinations have been developed to prevent the dissemination of the disease. To date, 71 cases of Graves' ...

    Abstract Objectives: Over the past 3 years, coronavirus disease 2019 with its worldwide spread has profoundly marked public health, therefore anti-COVID-19 vaccinations have been developed to prevent the dissemination of the disease. To date, 71 cases of Graves' disease (GD) after vaccination against SARS-Cov-2 were described in the adult population. Our goal is to present the first case in the paediatric population.
    Case presentation: We present the first case of a 16-year-old adolescent girl who developed GD 6-7 weeks after the second dose anti-COVID-19 mRNA vaccine. Therapy with methimazole and propranolol was started, achieving normal thyroid function and negativity of thyroid autoantibodies at the time of therapy discontinuation after 8 months.
    Conclusions: This case shows that the development of GD after COVID-19 mRNA vaccination can occur also in the adolescent population. Nevertheless, the small number of cases of GD described so far, after many millions of vaccinations, makes it impossible to determine whether this is simple a coincidence or a cause. Further epidemiological data on the incidence of GD in the vaccination period compared to the previous period will be able to clearly define this question.
    Language English
    Publishing date 2023-08-24
    Publishing country Germany
    Document type Case Reports
    ZDB-ID 1231070-0
    ISSN 2191-0251 ; 0334-018X
    ISSN (online) 2191-0251
    ISSN 0334-018X
    DOI 10.1515/jpem-2023-0181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

    Cozzolongo, Raffaele / Betterle, Corrado / Fabris, Paolo / Paola Albergoni, Maria / Lanzilotta, Elsa / Manghisi, Onofrio G

    European journal of gastroenterology & hepatology

    2006  Volume 18, Issue 6, Page(s) 689–692

    Abstract: ... with recombinant alpha-2b peginterferon combined with ribavirin for chronic hepatitis C. Serum samples, collected ... daily; the liver function tests are normal and serum hepatitis C virus RNA is negative. These data ...

    Abstract A 61-year-old man was observed to develop type 1 diabetes mellitus following a 3-month treatment with recombinant alpha-2b peginterferon combined with ribavirin for chronic hepatitis C. Serum samples, collected before the start of therapy and 2 months after the diagnosis of diabetes mellitus, revealed islet-cell antibodies at a titer of 20 and 40 JDF-U, respectively, and glutamic acid decarboxylase autoantibodies at a value of 76.5 and 196 IU/ml, respectively. Antibodies to second islet autoantigen were persistently negative. HLA class II typing revealed the presence of DRB1*04/DRB1*14, DQA1*0303-0104 and DQB1*04-0503 alleles. Eight months after the onset of type 1 diabetes mellitus, the patient is still receiving 30 IU insulin daily; the liver function tests are normal and serum hepatitis C virus RNA is negative. These data confirm that, in patients with potential diabetes mellitus, the disease may become manifest as a side-effect during therapy with peginterferon-alpha plus ribavirin. The patient as a candidate for interferon treatment should therefore be investigated, in addition to thyroid autoimmunity, also for pancreatic autoantibodies before starting therapy.
    MeSH term(s) Antiviral Agents/adverse effects ; Autoimmunity/immunology ; Chronic Disease ; Combined Modality Therapy ; Diabetes Mellitus, Type 1/chemically induced ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/immunology ; Humans ; Interferon alpha-2 ; Interferon-alpha/adverse effects ; Male ; Middle Aged ; Polyethylene Glycols ; Recombinant Proteins ; Ribavirin/therapeutic use ; Treatment Outcome
    Chemical Substances Antiviral Agents ; Interferon alpha-2 ; Interferon-alpha ; Recombinant Proteins ; Polyethylene Glycols (3WJQ0SDW1A) ; Ribavirin (49717AWG6K) ; peginterferon alfa-2b (G8RGG88B68)
    Language English
    Publishing date 2006-05-12
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 1034239-4
    ISSN 1473-5687 ; 0954-691X
    ISSN (online) 1473-5687
    ISSN 0954-691X
    DOI 10.1097/00042737-200606000-00018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.

    Fabris, P / Floreani, A / Tositti, G / Vergani, D / De Lalla, F / Betterle, C

    Alimentary pharmacology & therapeutics

    2003  Volume 18, Issue 6, Page(s) 549–558

    Abstract: ... by pancreatic beta cell destruction. It has been reported that chronic hepatitis C infection is associated with type 2 ... in hepatitis C virus-positive patients is not significantly different to that reported in the general population ... published. Type 1 diabetes mellitus occurs more frequently in patients treated for chronic hepatitis C ...

    Abstract Type 1 diabetes mellitus is the result of an autoimmune process characterized by pancreatic beta cell destruction. It has been reported that chronic hepatitis C infection is associated with type 2 diabetes mellitus, but not with type 1. Although the prevalence of markers of pancreatic autoimmunity in hepatitis C virus-positive patients is not significantly different to that reported in the general population, it increases during alpha-interferon therapy from 3 to 7%, probably due to the immunostimulatory effects of this cytokine. To date, 31 case reports of type 1 diabetes mellitus related to interferon treatment have been published. Type 1 diabetes mellitus occurs more frequently in patients treated for chronic hepatitis C than for other conditions and is irreversible in most cases. In 50% of these patients, markers of pancreatic autoimmunity predated treatment, the majority of cases having a genetic predisposition. Thus, in predisposed individuals, alpha-interferon can either induce or accelerate a diabetogenic process already underway. We suggest that islet cell autoantibodies and glutamic acid decarboxylase autoantibodies should be investigated before and during interferon treatment in order to identify subjects at high risk of developing type 1 diabetes mellitus.
    MeSH term(s) Antiviral Agents/adverse effects ; Antiviral Agents/immunology ; Autoantibodies/immunology ; Diabetes Mellitus, Type 1/chemically induced ; Diabetes Mellitus, Type 1/immunology ; Glutamate Decarboxylase/immunology ; Hepatitis C, Chronic ; Humans ; Interferons/adverse effects ; Interferons/immunology ; Islets of Langerhans/immunology
    Chemical Substances Antiviral Agents ; Autoantibodies ; Interferons (9008-11-1) ; Glutamate Decarboxylase (EC 4.1.1.15)
    Language English
    Publishing date 2003-09-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1046/j.1365-2036.2003.01681.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19.

    Sabbadin, Chiara / Betterle, Corrado / Scaroni, Carla / Ceccato, Filippo

    Frontiers in endocrinology

    2021  Volume 12, Page(s) 805647

    Abstract: Adrenal insufficiency (AI) is a life-threatening disorder, with increased morbidity and mortality, especially in case of an acute illness that can increase the requirement of cortisol. A novel infectious disease, termed Coronavirus Disease 2019 (COVID-19) ...

    Abstract Adrenal insufficiency (AI) is a life-threatening disorder, with increased morbidity and mortality, especially in case of an acute illness that can increase the requirement of cortisol. A novel infectious disease, termed Coronavirus Disease 2019 (COVID-19), appeared in 2020. Therefore, AI patients are experiencing a novel challenge: the risk of infection. In our experience, a prompt contact to the Endocrine center (with a telemedicine consultation) and a full awareness of diseases (cortisol deficiency, COVID-19 and the self-management of an adrenal crisis) are important to motivate patients. Vaccine is an effective treatment to prevent hospitalization and aggressive course of COVID-19. Some patients manifest challenges due to inequitable access and vaccine hesitancy, resulting in a delay in the acceptance of vaccines despite the availability of vaccination services. Therefore, an effort of all physicians must be conducted in order to advise patients with AI. In this short review, we try to answer some frequently asked questions regarding the management of patients with AI.
    MeSH term(s) Adrenal Insufficiency/epidemiology ; Adrenal Insufficiency/pathology ; Adrenal Insufficiency/prevention & control ; Adrenal Insufficiency/virology ; COVID-19/complications ; COVID-19/prevention & control ; COVID-19/virology ; COVID-19 Vaccines/administration & dosage ; Health Services Accessibility/statistics & numerical data ; Humans ; Risk Factors ; SARS-CoV-2/isolation & purification ; Telemedicine ; United States/epidemiology ; Vaccination Hesitancy/statistics & numerical data
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-12-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2592084-4
    ISSN 1664-2392
    ISSN 1664-2392
    DOI 10.3389/fendo.2021.805647
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Analysis of the

    Cudini, Annamaria / Nardella, Caterina / Bellacchio, Emanuele / Palma, Alessia / Delfino, Domenico Vittorio / Betterle, Corrado / Cappa, Marco / Fierabracci, Alessandra

    International journal of molecular sciences

    2024  Volume 25, Issue 5

    Abstract: Autoimmune polyglandular syndromes (APS) are classified into four main categories, APS1-APS4. APS1 is caused ... ...

    Abstract Autoimmune polyglandular syndromes (APS) are classified into four main categories, APS1-APS4. APS1 is caused by
    MeSH term(s) Humans ; Polyendocrinopathies, Autoimmune ; Syndrome ; Mutation ; Polymorphism, Single Nucleotide ; Promoter Regions, Genetic
    Language English
    Publishing date 2024-02-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25052656
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Vaccinations and Autoimmune Diseases.

    Olivieri, Bianca / Betterle, Corrado / Zanoni, Giovanna

    Vaccines

    2021  Volume 9, Issue 8

    Abstract: Vaccines represent one of the most effective measures of public health medicine, saving countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however, no vaccine is completely free from risks and adverse events can occur ... ...

    Abstract Vaccines represent one of the most effective measures of public health medicine, saving countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however, no vaccine is completely free from risks and adverse events can occur following vaccination. An adverse event following immunization (AEFI) may be a true adverse reaction caused by the vaccine or an event that temporally occurred after immunization but is not caused by it. Among the adverse reactions to vaccines, one of the most feared is the triggering of autoimmune diseases, which are a heterogeneous group of disorders characterized by dysregulation of the immune system. Currently, no mechanisms have been demonstrated that could explain the correlation between vaccination and the development of autoimmune diseases. Furthermore, epidemiological studies do not support the hypothesis that vaccines cause systemic autoimmune diseases. The only confirmed associations, although very rare, are those between the flu vaccine and Guillain-Barré syndrome, especially with old vaccine preparations, and measles-mumps-rubella (MMR) vaccine and thrombocytopenia. Due to the SARS-CoV2 pandemic, new types of vaccines have been developed and are now available. Close vaccine safety-surveillance is currently underway for these new vaccines.
    Language English
    Publishing date 2021-07-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9080815
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top